<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01202175</url>
  </required_header>
  <id_info>
    <org_study_id>100353</org_study_id>
    <nct_id>NCT01202175</nct_id>
  </id_info>
  <brief_title>Effects of the Beta-blocker Nebivolol (Bystolic) on Subjects With High Normal Blood Pressure and/or a Family History of Hypertension</brief_title>
  <official_title>Effects of the Novel Beta-adrenergic Antagonist Nebivolol (Bystolic) on Prehypertensive Subjects at Genetic Risk of Hypertension: Implications for Inflammation, Endothelial Dysfunction, and Oxidative Stress.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <brief_summary>
    <textblock>
      The investigators aim to evaluate subjects at high risk of future development of
      hypertension, those with a family history of hypertension and/or that already have high
      normal(SBP 120-139 mmHg or DBP 80-89 mmHg) blood pressure. The investigators plan to
      investigate whether these subjects have the same markers (such as microscopic protein in the
      urine or C-reactive protein in the blood) in the blood and urine that people with high blood
      pressure have, and whether they are improved before and after taking the beta-blocker
      nebivolol.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Aortic Systolic Blood Pressure (SBP)</measure>
    <time_frame>Basline (visit 1) and 8 weeks (visit 2)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Aortic Diastolic Blood Pressure (DBP)</measure>
    <time_frame>Basline (visit 1) and 8 weeks (visit 2)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Aortic Mean Arterial Pressure (MAP)</measure>
    <time_frame>Basline (visit 1) and 8 weeks (visit 2)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Aortic Pulse Pressure</measure>
    <time_frame>Basline (visit 1) and 8 weeks (visit 2)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Aortic Augmentation Pressure</measure>
    <time_frame>Basline (visit 1) and 8 weeks (visit 2)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Aortic Augmentation Index for Heart Rate</measure>
    <time_frame>Basline (visit 1) and 8 weeks (visit 2)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulse Wave Velocity</measure>
    <time_frame>Basline (visit 1) and 8 weeks (visit 2)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart Rate, Beats Per a Minute</measure>
    <time_frame>Basline (visit 1) and 8 weeks (visit 2)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urinary Nitric Oxide Excretion</measure>
    <time_frame>Basline (visit 1) and 8 weeks (visit 2)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Isoprostane Excretion</measure>
    <time_frame>Basline (visit 1) and 8 weeks (visit 2)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Hydrogen Peroxide Excretion</measure>
    <time_frame>Baseline (visit 1) and 8 Weeks (visit 2)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Interleukin Levels</measure>
    <time_frame>Basline (visit 1) and 8 weeks (visit 2)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Pre-hypertension</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Nebivolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebivolol</intervention_name>
    <description>Oral nebivolol 2.5-5mg once daily</description>
    <arm_group_label>Nebivolol</arm_group_label>
    <arm_group_label>Sugar pill</arm_group_label>
    <other_name>Bystolic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  â€¢ Prehypertensive male and female subjects with SBP =120-139 or DBP =80-89 with at
             least one known family member (must be diagnosed prior to the age of 60) with
             essential hypertension (confirmation may be sought).

               -  All ethnicities

               -  Non-smokers and non-drug abusers, no current smoking or illicit drug use in the
                  prior 3 months.

               -  Aged 18-40 years

               -  No known serious medical conditions requiring close monitoring from physicians-
                  such as liver impairment, chronic kidney disease, or diabetes mellitus

               -  Subjects will need to remain in the San Diego area for the duration of the study
                  (10 weeks) and be accessible by telephone or email.

               -  Female subjects must be willing to use a birth control method, such as
                  abstinence, birth control pills, diaphragm, condom, or intrauterine device to
                  prevent pregnancy during the study.

        Exclusion Criteria:

          -  Subjects with SBP &gt;140 or SBP&lt;120 or DBP &gt;90 and DBP&lt;80

          -  We will exclude subjects whose family members have known secondary etiologies for
             hypertension such as hyperaldosteronism or Cushing's Disease.

          -  Subjects cannot have a chronic medical condition that is actively treated by a
             physician, such as liver impairment, diabetes, or kidney disease

          -  History of bronchial asthma or chronic obstructive pulmonary disease

          -  Subjects cannot be on any anti-hypertensive medications for any reason.

          -  Subjects may not have previous intolerance, hypersensitivity, or allergy to any beta
             blocker therapy or may have contraindications to beta blocker therapy such as asthma,
             bradycardia, etc.

          -  Subjects may not be taking medications which may affect the metabolism of nebivolol,
             such as those that inhibit CYP2D6 (such as fluoxetine or cimetidine)

          -  Nursing women, pregnant women, or those that plan to become pregnant in the study
             period will also be excluded. (Pregnancy tests will be performed on all female
             subjects at the start of the study)

          -  Subjects with pulse rate consistently &lt;60 beats per minute or evidence of arrythmias
             including atrioventricular block.

          -  Those that have smoked or used illicit drugs within the past 3 months

          -  Female subjects that are not willing to use a birth control method, such as
             abstinence, birth control pills, diaphragm, condom, or intrauterine device to prevent
             pregnancy during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel O'Connor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 24, 2010</study_first_submitted>
  <study_first_submitted_qc>September 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2010</study_first_posted>
  <results_first_submitted>July 9, 2019</results_first_submitted>
  <results_first_submitted_qc>July 30, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 21, 2019</results_first_posted>
  <last_update_submitted>July 30, 2019</last_update_submitted>
  <last_update_submitted_qc>July 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Joachim H. Ix</investigator_full_name>
    <investigator_title>Professor of medicine</investigator_title>
  </responsible_party>
  <keyword>Genetic risk of hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Prehypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nebivolol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study results are being entered according to a publication that was published before PI passed away. According to the publication; two participants dropped out because of flu-like symptoms, 2 were lost to follow-up, and 1 dropped out of the study after the initial visit but never took the medication. It is unknown what arm they were in.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>All Study Participants</title>
          <description>Oral nebivolol 5 mg once daily or Placebo (sugar pill) once dailly. Arms/Groups are combined in this module because the only access to data is a publication that was published before Principal Invesitgator passed away. According to the publication; two participants dropped out because of flu-like symptoms, 2 were lost to follow-up, and 1 dropped out of the study after the initial visit but never took the medication. It is unknown what arm they were in.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Nebivolol</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Pacebo</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nebivolol</title>
          <description>Nebivolol: Oral nebivolol 5 mg once daily</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.1" spread="1.8"/>
                    <measurement group_id="B2" value="30.4" spread="1.6"/>
                    <measurement group_id="B3" value="33.7" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.55" spread="0.92"/>
                    <measurement group_id="B2" value="31.03" spread="1.14"/>
                    <measurement group_id="B3" value="29.79" spread=".86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Starting systolic blood pressure</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="127.4" spread="1.6"/>
                    <measurement group_id="B2" value="126.2" spread="1.5"/>
                    <measurement group_id="B3" value="126.8" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Starting diastolic blood pressure</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84.7" spread="1.5"/>
                    <measurement group_id="B2" value="84.4" spread="1.0"/>
                    <measurement group_id="B3" value="84.5" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Aortic Systolic Blood Pressure (SBP)</title>
        <time_frame>Basline (visit 1) and 8 weeks (visit 2)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nebivolol</title>
            <description>Nebivolol: Oral nebivolol 5 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Aortic Systolic Blood Pressure (SBP)</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (visit 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.7" spread="2.5"/>
                    <measurement group_id="O2" value="107.7" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (visit 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106.2" spread="2.4"/>
                    <measurement group_id="O2" value="106.6" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Aortic Diastolic Blood Pressure (DBP)</title>
        <time_frame>Basline (visit 1) and 8 weeks (visit 2)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nebivolol</title>
            <description>Nebivolol: Oral nebivolol 5 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Aortic Diastolic Blood Pressure (DBP)</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (visit 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.1" spread="2.3"/>
                    <measurement group_id="O2" value="75.9" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (visit 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.3" spread="1.9"/>
                    <measurement group_id="O2" value="74" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Aortic Mean Arterial Pressure (MAP)</title>
        <time_frame>Basline (visit 1) and 8 weeks (visit 2)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nebivolol</title>
            <description>Nebivolol: Oral nebivolol 5 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Aortic Mean Arterial Pressure (MAP)</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (visit 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.2" spread="2.1"/>
                    <measurement group_id="O2" value="90.4" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (visit 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.8" spread="1.9"/>
                    <measurement group_id="O2" value="88.6" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Aortic Pulse Pressure</title>
        <time_frame>Basline (visit 1) and 8 weeks (visit 2)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nebivolol</title>
            <description>Nebivolol: Oral nebivolol 5 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Aortic Pulse Pressure</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (visit 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.6" spread="2.3"/>
                    <measurement group_id="O2" value="31.8" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (visit 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.9" spread="1.8"/>
                    <measurement group_id="O2" value="32.6" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Aortic Augmentation Pressure</title>
        <time_frame>Basline (visit 1) and 8 weeks (visit 2)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nebivolol</title>
            <description>Nebivolol: Oral nebivolol 5 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Aortic Augmentation Pressure</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (visit 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" spread="2.0"/>
                    <measurement group_id="O2" value="5.5" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (visit 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" spread="1.6"/>
                    <measurement group_id="O2" value="5.3" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Aortic Augmentation Index for Heart Rate</title>
        <time_frame>Basline (visit 1) and 8 weeks (visit 2)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nebivolol</title>
            <description>Nebivolol: Oral nebivolol 5 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Aortic Augmentation Index for Heart Rate</title>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (visit 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7" spread="3.4"/>
                    <measurement group_id="O2" value="14.5" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (visit 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" spread="3.8"/>
                    <measurement group_id="O2" value="12.8" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pulse Wave Velocity</title>
        <time_frame>Basline (visit 1) and 8 weeks (visit 2)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nebivolol</title>
            <description>Nebivolol: Oral nebivolol 5 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Pulse Wave Velocity</title>
          <units>m/s</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (visit 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.73" spread="0.28"/>
                    <measurement group_id="O2" value="5.95" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (visit 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.00" spread="0.18"/>
                    <measurement group_id="O2" value="5.78" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Heart Rate, Beats Per a Minute</title>
        <time_frame>Basline (visit 1) and 8 weeks (visit 2)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nebivolol</title>
            <description>Nebivolol: Oral nebivolol 5 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Heart Rate, Beats Per a Minute</title>
          <units>beats per a minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (visit 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.0" spread="1.9"/>
                    <measurement group_id="O2" value="75.6" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (visit 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.4" spread="2.3"/>
                    <measurement group_id="O2" value="72.1" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urinary Nitric Oxide Excretion</title>
        <time_frame>Basline (visit 1) and 8 weeks (visit 2)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nebivolol</title>
            <description>Nebivolol: Oral nebivolol 5 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Urinary Nitric Oxide Excretion</title>
          <units>umol/ mg Cr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (visit 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.31" spread="5.05"/>
                    <measurement group_id="O2" value="61.77" spread="11.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (visit 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.38" spread="14.25"/>
                    <measurement group_id="O2" value="65.54" spread="10.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urinary Isoprostane Excretion</title>
        <time_frame>Basline (visit 1) and 8 weeks (visit 2)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nebivolol</title>
            <description>Nebivolol: Oral nebivolol 5 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Urinary Isoprostane Excretion</title>
          <units>pg/ mg Cr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (visit 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="180" spread="14"/>
                    <measurement group_id="O2" value="165" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (visit 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="213" spread="20"/>
                    <measurement group_id="O2" value="185" spread="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urinary Hydrogen Peroxide Excretion</title>
        <time_frame>Baseline (visit 1) and 8 Weeks (visit 2)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nebivolol</title>
            <description>Nebivolol: Oral nebivolol 5 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Urinary Hydrogen Peroxide Excretion</title>
          <units>umol/ mg Cr</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (visit 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.652" spread="0.274"/>
                    <measurement group_id="O2" value="0.500" spread="0.281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (visit 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.79" spread="1.83"/>
                    <measurement group_id="O2" value="0.578" spread="0.194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Interleukin Levels</title>
        <time_frame>Basline (visit 1) and 8 weeks (visit 2)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nebivolol</title>
            <description>Nebivolol: Oral nebivolol 5 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Plasma Interleukin Levels</title>
          <units>pg/ mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (visit 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.626" spread="0.598"/>
                    <measurement group_id="O2" value="1.351" spread="0.258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (visit 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.647" spread="0.689"/>
                    <measurement group_id="O2" value="1.351" spread="0.258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>All Study Particpants</title>
          <description>Oral nebivolol 5 mg once daily or Placebo (sugar pill) once dailly. Arms/Groups are combined in this module because the only access to data is a publication that was published before Principal Invesitgator passed away. According to the publication; two participants dropped out because of flu-like symptoms, 2 were lost to follow-up, and 1 dropped out of the study after the initial visit but never took the medication. It is unknown what arm they were in.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Flue like symptoms</sub_title>
                <counts group_id="E1" events="50" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Joachim H. Ix, MD, MAS</name_or_title>
      <organization>Univeristy of California, San Diego</organization>
      <phone>858-552-7528</phone>
      <email>joeix@ucsd.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

